Testing Suizenji for newly diagnosed pancreatic cancer
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This trial tests a new ultrasound treatment called Suizenji for people with pancreatic cancer that cannot be removed by surgery. The goal is to see if it can safely target the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of pancreatic cancer that has spread or cannot be removed.
- You have not had any chemotherapy or other cancer treatment for this cancer yet.
- Your tumor can be seen on an ultrasound and can be reached by the ultrasound waves.
- You are age 18 or older and in generally good health (able to care for yourself).
- Your liver and kidney function are adequate based on routine blood tests.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new imaging procedure called LINFU® that may help doctors better detect pancreatic cancer. You may join if you have symptoms or an abnormal scan that suggests pancreatic cancer, and you're scheduled for a biopsy.
This trial tests whether adding focused ultrasound (IMD10) to standard chemotherapy helps treat pancreatic cancer that is borderline or locally advanced and cannot be removed by surgery right away. It may shrink the tumor enough to allow surgery later.
This trial tests adding surufatinib (a targeted therapy) to standard chemotherapy (gemcitabine and nab-paclitaxel) for people with locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if the combination helps shrink or control the tumor better.
This trial tests a new drug called mitazalimab injected directly into the tumor, combined with a special electrical procedure that kills cancer cells. It is for people whose pancreatic cancer has not spread but cannot be removed by surgery.
This study uses small pancreatic cancer samples grown in the lab to understand which treatments may work best for people with pancreatic cancer. It may help researchers better “profile” tumors so standard care can be matched to the most effective options.
This trial studies whether a combination of surufatinib and immunotherapy (camrelizumab, plus an “AS” medicine) can slow or shrink advanced pancreatic cancer that has spread. It is for people starting treatment for advanced disease for the first time and may help those who have measurable tumors and meet safety test limits.
Hear when a new Pancreatic cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.